Summer Sale
50% off Premium Yearly
TSE:PRM
Harvest Big Pharma Split Corp. (PRM.TO)
Financials 
Technical Analysis 
Jun 11, 2026, 12:00 amThis summary was created by AI, based on 2 opinions in the last 12 months.
Harvest Big Pharma Split Corp. (PRM-T) is positioned as a strong investment opportunity, with portfolio holdings that include the ten largest pharmaceutical and biotech companies globally. The fund employs a strategy that balances underlying shares with dividends and options, which helps to create an enhanced yield for investors. Current yields exceed 8%, making it attractive for income-focused investors. Analysts highlight the fund's performance during market downturns, showcasing its resilience and the ability to maintain and even increase value. With a recommended stop-loss and projections indicating significant upside potential, experts advocate for PRM as a preferable choice for investors seeking stability and growth in the pharma sector.
;fill-opacity:1;'/%3e%3cpath%20d='M31%2018.6001V30H8V18.6001L14.1334%2022.4334L19.4999%2014L24.8669%2022.4334L31%2018.6001Z'%20fill='%23EE5432'%20style='fill:%23EE5432;fill:color(display-p3%200.9340%200.3310%200.1956);fill-opacity:1;'/%3e%3c/svg%3e){kind=small}
Premium contentPRM hold a portfolio of 10 of the world's largest pharmaceutical and biotechnology companies. The fund managers use a balance of the underlying shares with dividends and options to create an enhanced yield. We like that recent earnings show healthy and growing cash reserves. The shares held their value during the severe market downturns in 2018 and 2022 -- actually increasing 11% in each -- providing good market volatility protection. We recommend setting a stop-loss at $10.00, looking to achieve $15.00 -- upside potential of 18%. Yield 7.2%
- «
- ‹
- 1
- ›
- »
Harvest Big Pharma Split Corp. (PRM.TO) Frequently Asked Questions
What is Harvest Big Pharma Split Corp. stock symbol?
Harvest Big Pharma Split Corp. is a Canadian stock, trading under the symbol PRM.TO (previously PRM-T on Stockchase) on the Toronto Stock Exchange (PRM-CT). It is usually referred to as TSX:PRM or PRM.TO
Is Harvest Big Pharma Split Corp. a buy or a sell?
In the last year, 2 stock analysts issued a Buy, Sell, or Hold rating on PRM.TO (previously PRM-T on Stockchase). 2 analysts recommended to BUY and 0 analysts recommended to SELL the stock. The latest stock analyst rating is TOP PICK. Read the latest stock experts' ratings for Harvest Big Pharma Split Corp..
Is Harvest Big Pharma Split Corp. a good investment or a top pick?
Harvest Big Pharma Split Corp. was recommended as a Top Pick by The Panic-Proof Portfolio (Stockchase Research) on 2025-11-04. Read the latest stock experts ratings for Harvest Big Pharma Split Corp..
Why is Harvest Big Pharma Split Corp. stock dropping?
Earnings reports or recent company news can cause the stock price to drop. Read stock experts' recommendations for Harvest Big Pharma Split Corp..
Is Harvest Big Pharma Split Corp. worth watching?
Harvest Big Pharma Split Corp. is followed by 9 investors on Stockchase and is a trending stock that is worth watching.
What is Harvest Big Pharma Split Corp. stock price?
On 2026-06-12, Harvest Big Pharma Split Corp. (PRM.TO) stock closed at a price of $13.70.
We reiterate PRM, a portfolio of the 10 world's largest pharma and biotech companies, as a TOP PICK. The fund manages a balance of underlying shares with dividends and options to create an enhanced yield for investors, which presently yields over 8%. We recommend trailing up the stop (from $10) to $13, looking to achieve $18 -- upside over 18%. Yield 8.2%
(Analysts’ price target is $32.78)